Connect with us

Technology

UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024

Published

on

ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis (AD) has successfully completedResults from the ADESOS study have been selected for an oral presentation at the late breaking research sessions at the RAVE Conference 2024Orismilast is a next generation, high potency PDE4 B/D selective inhibitor with reported positive results from a Phase 2b study in psoriasis and Phase 2 study in hidradenitis suppurativa (HS); orismilast is currently being evaluated in an ongoing IIT study in ulcerative colitis (UC)UNION is progressing orismilast to Phase 3 development in AD

HELLERUP, Denmark, June 4, 2024 /PRNewswire/ — UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announces successful completion of the ADESOS Phase 2b, randomized, dose-finding study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe AD.

Topline results from the ADESOS study have been selected for an oral presentation by the Signatory Investigator, Professor Jonathan Silverberg, MD, PhD, MPH at the late breaking research sessions at Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) Conference on June 8-10, 2024, in Chicago, United States. It will be the first presentation of data from the ADESOS study.

Presentation details

Presentation: Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a Phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS)

Presenter: Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Signatory Investigator for ADESOS

Date and time: Monday June 10, 2024, at 1:30 PM – 4:40 PM CDT.

Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Signatory Investigator for ADESOS study, said: 

“AD is one of the most common chronic inflammatory skin diseases worldwide. Innovation in recent years has brought good injectable treatments to patients, but a significant unmet medical need for a safe and effective oral treatment still exists. Orismilast offers the potential for a safe oral treatment with early itch reduction and holds a significant promise as a novel treatment option in AD.”

Kim Kjøller, Co-Chief Executive Officer of UNION therapeutics, adds:

“The results from the ADESOS study with orismilast in atopic dermatitis (AD) follows positive read outs in psoriasis and hidradenitis suppurativa (HS) confirming the potential of orismilast as a safe oral treatment across immunology. We are pleased that the Phase 2b results from the ADESOS study have been selected for an oral presentation at the RAVE Conference in Chicago and look forward to the results being shared and discussed with the leading experts in the field.”

Orismilast is developed as a next-generation, high potency PDE4B/D selective inhibitor targeting first-in-class positions in AD and hidradenitis suppurativa (HS), and best in class in psoriasis. The efficacy and safety profile of orismilast have been evaluated in the previously reported IASOS Phase 2b study in psoriasis and OSIRIS Phase 2 study in HS. Data of these studies has been presented at leading scientific conferences and data is published in peer-reviewed journals, including the Journal of American Academy of Dermatology (JAAD) and the Journal of European Academy of Dermatology and Venerology (JEADV).

UNION has scheduled an End of Phase 2 meeting with the FDA to discuss advancing the orismilast development program into Phase 3 studies in AD.  

About the ADESOS Phase 2b study

The Phase 2b study was a randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of orismilast in patients with moderate to severe AD. The study included 233 patients who were randomized to three active doses (20mg, 30mg, and 40 mg) of orismilast or placebo administered twice daily. The study was conducted in centers in Europe and in the US.

About orismilast

Orismilast is a next generation, high potency PDE4 inhibitor targeting the PDE4B/D subtypes linked to inflammation, demonstrating potent inhibition of Th1, Th2 and Th17 pathways. It acts early in the inflammation cascade, inducing a broad range of anti-inflammatory effects across multiple cytokines involved in many dermatological and immunological diseases.1) 

UNION is developing orismilast as an oral treatment, based on the well-known safety profile of the PDE4 class, across immunology, initially targeting best-in-class or first-in-class positions in atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis and ulcerative colitis (UC).

The FDA has cleared UNION’s Investigational New Drug (IND) application for orismilast and granted Fast Track designation for orismilast for the treatment of moderate to severe AD as well as for the treatment of moderate to severe HS.

About atopic dermatitis

AD is a chronic inflammatory skin disease affecting 2.1-4.9 % of the adult population worldwide and is the most common skin disease among children.2) There were approximately 20 million diagnosed moderate-to-severe adult patients with AD in 2023 in the Seven Major Markets (United States, France, Germany, Italy, Spain, UK, and Japan).3) Disease symptoms are characterized by recurrent eczematous skin lesions and intense itch. AD has a substantial psychosocial impact on patients and relatives.4) During disease flares, approximately 80% of patients may experience disturbed sleep, which may also disrupt the sleep of family members.5) The disease also appears to impact the mood and patients have an increased risk of anxiety and depression.6) 

Sources

1)       Blauvelt A et al., Dermatology and Therapy 2023: Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review – PubMed (nih.gov) &
Silverberg J.I. et al., JEADV 2022: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18818  &
Warren R.B. et al., JEADV 2022: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18812 

2)       Barbarot S et al,. Allergy 2018: https://pubmed.ncbi.nlm.nih.gov/29319189/  https://pubmed.ncbi.nlm.nih.gov/25925336/

3)       EvaluatePharma 2023

4)       Laughter MR et al., British Journal of Dermatology 2021: https://pubmed.ncbi.nlm.nih.gov/33006135/ 

5)       Eichenfield LF et al., Journal of the American Academy of Dermatology 2014: https://pubmed.ncbi.nlm.nih.gov/24290431/

6)       Drucker AM et al., The Journal of Investigative Dermatology 2017: https://pubmed.ncbi.nlm.nih.gov/27616422/

Contacts

Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
morten.boesen@uniontherapeutics.com

Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S
+45 5385 3044
sarah.toft-joergensen@uniontherapeutics.com

About UNION therapeutics

UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-successful-completion-of-the-adesos-phase-2b-study-and-presentation-of-,c3994646

 

View original content:https://www.prnewswire.co.uk/news-releases/union-therapeutics-announces-successful-completion-of-the-adesos-phase-2b-study-and-presentation-of-data-at-the-rave-conference-2024-302162871.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Sidus Space Announces Closing of Offering

Published

on

By

CAPE CANAVERAL, Fla., April 21, 2026 /PRNewswire/ — Sidus Space, Inc. (Nasdaq: SIDU) (“Sidus” or the “Company”), an innovative space and defense technology company, today announced the closing of its previously announced best-efforts offering of 13,453,700 shares of its Class A common stock (or pre-funded warrants (“Pre-funded Warrants”) in lieu thereof). Each share of Class A common stock (or Pre-funded Warrant) was sold at an offering price of $4.35 per share (inclusive of the Pre-funded Warrant exercise price) for gross proceeds of approximately $58.5 million, before deducting the placement agent’s fees and offering expenses. All of the shares of Class A common stock and Pre-funded Warrants were offered by the Company.

The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

ThinkEquity acted as sole placement agent for the offering.

The securities were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-292839), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 20, 2026, and declared effective on February 4, 2026. The offering was made by means of a written prospectus. A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and made available on the SEC’s website. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Sidus Space

Sidus Space (NASDAQ: SIDU) is an innovative space and defense technology company offering flexible, cost-effective solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid innovation, adaptable and cost-effective solutions, and the optimization of space systems and data collection performance. With demonstrated space heritage, including manufacturing and operating its own satellite and sensor system, LizzieSat®, Sidus Space serves government, defense, intelligence, and commercial companies around the globe. Strategically headquartered on Florida’s Space Coast, Sidus Space operates a 35,000-square-foot space manufacturing, assembly, integration, and testing facility and provides easy access to nearby launch facilities. For more information, visit: sidusspace.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute ‘forward-looking statements’ within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words ‘anticipate,’ ‘believe,’ ‘continue,’ ‘could,’ ‘estimate,’ ‘expect,’ ‘intend,’ ‘may,’ ‘plan,’ ‘potential,’ ‘predict,’ ‘project,’ ‘should,’ ‘target,’ ‘will,’ ‘would’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Sidus Space’s prospectus supplement and Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Sidus Space, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations
Investor-Relations@sidusspace.com

Media
press@sidusspace.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/sidus-space-announces-closing-of-offering-302749177.html

SOURCE Sidus Space, Inc.

Continue Reading

Technology

Ezee Fiber Connects First Customers in Santa Fe, Accelerates New Mexico Expansion

Published

on

By

HOUSTON, April 21, 2026 /PRNewswire/ — Ezee Fiber, a fast-growing fiber internet company delivering 100% fiber-to-the-home (FTTH) service, announced it has connected its first customers in Santa Fe, New Mexico. This milestone marks the company’s first major step in building its Santa Fe network and expanding multi-gigabit, symmetrical fiber service across the state.

Installations are now underway, giving residents access to Ezee Fiber’s high-performance network, which features symmetrical multi-gig speeds, no data caps, no hidden fees and transparent lifetime pricing. The company also emphasizes locally staffed customer support and a reliable, high-quality experience that sets it apart from legacy providers.

“We’re excited to bring our modern, 100% fiber network to homes the state capital,” said Carlos Rosas, Senior Vice President and General Manager, Southwest Region at Ezee Fiber. “Communities deserve more than basic connectivity. We are focused on delivering ultra-fast speeds, reliability and long-term infrastructure that supports how people live and work today.”

Ezee Fiber began expanding in New Mexico in 2024 and continues to scale rapidly. In addition to Santa Fe, the company is building fiber infrastructure in Albuquerque and surrounding communities, with service activating on a rolling basis as construction is completed.

Residents can expect construction activity to move efficiently through neighborhoods. Ezee Fiber will provide advance notice before work begins and will restore all areas in line with municipal requirements and industry best practices.

Residents can check availability and learn more at ezeefiber.com.

About Ezee Fiber

Ezee Fiber is a rapidly growing fiber internet company delivering premium multi-gig service to residential, business, and government customers over a 100% fiber-optic network—at exceptional value.

The company’s carrier-grade infrastructure spans Texas, New Mexico, Illinois, Oregon, Michigan and Washington, supported by local teams who live and work in the communities they serve. Ezee Fiber’s industry-leading speeds, award-winning customer service, and transparent pricing model set the company apart. Learn more at www.ezeefiber.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ezee-fiber-connects-first-customers-in-santa-fe-accelerates-new-mexico-expansion-302749195.html

SOURCE Ezee Fiber

Continue Reading

Technology

CFA Institute calls for functional, proportionate AI oversight to safeguard UK retail investors and market integrity

Published

on

By

LONDON, April 21, 2026 /PRNewswire/ — CFA Institute, the global association of investment professionals, has published its response to the Financial Conduct Authority’s (FCA) Review into the long-term impact of artificial intelligence on retail financial services (the “Mills Review”). CFA Institute welcomes the FCA’s technology-neutral approach, while urging greater operational clarity to ensure responsible AI deployment.

In its submission, CFA Institute supports anchoring AI oversight within the UK’s existing principles-based framework, including the Consumer Duty and the Senior Managers and Certification Regime (SM&CR), rather than introducing a standalone AI rulebook. However, it emphasizes that supervisory expectations must be clearer and more practical as AI systems move from assistive tools to advisory functions and, ultimately, autonomous agents.

CFA Institute argues that regulation should follow what AI systems do for consumers, not how they are labelled or constructed. AI-enabled retail interfaces may generate “advice-like” outcomes, such as personalized product steering or portfolio construction guidance, without formally crossing regulatory thresholds. A substance-over-form approach is therefore essential to prevent regulatory arbitrage and ensure consistent consumer protection.

While the Consumer Duty provides a robust foundation, CFA Institute calls for AI-specific articulation of how its four outcomes apply where decision-making is increasingly delegated to automated systems. In particular, the response highlights a risk of automation bias, which may reduce effective consumer outcomes, especially among vulnerable customers.

Firms should be expected to test, monitor and evidence outcomes based on how consumers actually use AI systems in practice, not solely on how they are intended to function.

The submission also identifies a potential governance gap where firms report formal accountability for AI systems yet lack deep operational understanding of complex or third-party models. CFA Institute recommends clearer expectations around what “reasonable steps” and “meaningful oversight” mean under SM&CR and SYSC when AI is deployed in material retail use cases.

It further calls for:

A proportionate, tiered governance framework aligned to the assistive–advisory–autonomous spectrumClear allocation of end-to-end accountability for consumer outcomesReinforced oversight of third-party AI dependencies and operational resilience risks.

Although retail-focused, the response underscores broader market structure implications, including model concentration, correlated behavior, and third-party dependencies that could amplify volatility in stressed conditions. CFA Institute encourages close coordination between the FCA and the Bank of England, as well as continued alignment with IOSCO and the Financial Stability Board, to reduce fragmentation and support the UK’s global competitiveness.

Finally, CFA Institute stresses that responsible AI adoption depends on developing “hybrid” talent, professionals who combine technological fluency with fiduciary judgement and market expertise. Strengthening professional standards and supervisory capability should form part of the UK’s long-term AI competitiveness strategy.

Olivier Fines, CFA, Head of Advocacy and Capital Markets Policy at CFA Institute, said: “Artificial intelligence has the potential to expand access, improve efficiency and strengthen retail financial services, but only if trust and accountability remain firmly at the center.

“The UK’s principles-based framework is advantageous. The priority now is operational clarity: clear guidance on how the Consumer Duty and SM&CR apply when decision-making is increasingly delegated to AI systems.

“Regulation should follow function, not technological form. Where AI systems effectively shape or execute consumer decisions, protections must apply in substance, not just in label.

“We encourage the FCA to provide practical supervisory guidance by the end of 2026 and to continue close dialogue with industry and international standard-setters. With proportionate safeguards, meaningful oversight and investment in hybrid professional skills, the UK can play a leading role in responsible AI-enabled finance while preserving market integrity and public trust.”

About CFA Institute

As the global association of investment professionals, CFA Institute sets the standards for professional excellence and credentials. We champion ethical behavior in investment markets and serve as the leading source of learning and research for the investment industry. We believe in fostering an environment where investors’ interests come first, markets function at their best, and economies grow. With more than 200,000 charterholders worldwide across more than 160 markets, CFA Institute has 9 offices and 157 local societies. Find us at https://www.cfainstitute.org/ or follow us on LinkedIn, and subscribe on YouTube.

 

 

 

View original content:https://www.prnewswire.co.uk/news-releases/cfa-institute-calls-for-functional-proportionate-ai-oversight-to-safeguard-uk-retail-investors-and-market-integrity-302748558.html

Continue Reading

Trending